1. Home
  2. QSI vs CBIO Comparison

QSI vs CBIO Comparison

Compare QSI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Quantum-Si Incorporated

QSI

Quantum-Si Incorporated

HOLD

Current Price

$1.39

Market Cap

273.7M

Sector

Health Care

ML Signal

HOLD

CBIO

Crescent Biopharma Inc. Common Stock

N/A

Current Price

$15.07

Market Cap

252.6M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
QSI
CBIO
Founded
2013
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
273.7M
252.6M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
QSI
CBIO
Price
$1.39
$15.07
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$2.88
$25.60
AVG Volume (30 Days)
6.2M
61.7K
Earning Date
11-05-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$3,177,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$219.33
N/A
P/E Ratio
N/A
N/A
Revenue Growth
40.20
N/A
52 Week Low
$0.95
$9.81
52 Week High
$5.77
$21.40

Technical Indicators

Market Signals
Indicator
QSI
CBIO
Relative Strength Index (RSI) 41.15 72.03
Support Level $1.19 $12.76
Resistance Level $1.40 $15.40
Average True Range (ATR) 0.12 0.60
MACD -0.00 0.19
Stochastic Oscillator 40.00 78.64

Price Performance

Historical Comparison
QSI
CBIO

About QSI Quantum-Si Incorporated

Quantum-Si Inc is a life sciences company focused on the development and commercialization of proteomics research tools. The company has designed and developed a hardware, consumable, and software solution to provide a solution for protein detection and analysis. It has developed a proprietary universal single-molecule detection platform that enables Next-Generation Protein Sequencing (NGPS), the ability to sequence proteins.

About CBIO Crescent Biopharma Inc. Common Stock

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: